Reactive antibodies against bacillus Calmette-Guerin heat-shock protein-65 potentially predict the outcome of immunotherapy for high-grade transitional cell carcinoma of the bladder

Cancer

Volumn 116, Issue 3, 2010, Pages 600-609

  Ardelt, Peter U ^a   Kneitz, Burkhard ^a   Adam, Patrick ^a   Reiss, Cora ^a   Kocot, Arkadius ^a   Fensterle, Joachim ^a   Chen, Limor ^b   Pasqualini, Renata ^c   Arap, Wadih ^c   Gerharz, Elmar W ^a   Riedmiller, Hubertus ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b TEVA PHARMACEUTICALS   (Israel)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bacillus Calmette Guerin; Heat shock proteins; Immunotherapy; Transitional cell carcinoma

Indexed keywords

BCG VACCINE; HEAT SHOCK PROTEIN 65; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY;

AGED; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BCG VACCINATION; BLADDER CARCINOMA; CANCER IMMUNOTHERAPY; CARCINOMA IN SITU; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; HUMAN; MALE; MYCOBACTERIUM BOVIS; PREDICTION; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; ANTIBODIES, BACTERIAL; BCG VACCINE; BIOLOGICAL MARKERS; CARCINOMA, TRANSITIONAL CELL; HEAT-SHOCK PROTEINS; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM BOVIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 76249098429     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24770     Document Type: Article

References (24)

1. Murakami T, Ebara S, Saika T, et al. Routine transurethral biopsy of the bladder is not necessary to evaluate the response to bacillus Calmette-Guerin therapy. Acta Med Okayama. 2007;61:341-344.
2. Morales A, Eideger D, Bruce A. Intracavitary bacillus Calmette-Guerin in the superficial bladder tumor. J Urol. 1976;116:180-183.
3. Sharma P, Old LJ, Allison JP. Immunotherapeutic strategies for high-risk bladder cancer. Semin Oncol. 2007;34: 165-172.
4. Herr HW, Schwalb DM, Zhang ZF, et al. Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol. 1995;13:1404-1408.
5. Alexandroff AB, Jackson AM, O'Donnell MA, James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet. 1999;353:1689-1694.
6. Saint F, Patard JJ, Maille P, et al. T helper 1/2 lymphocyte urinary cytokine profiles in responding and nonresponding patients after 1 and 2 courses of bacillus Calmette-Guerin for superficial bladder cancer. J Urol. 2001;166:2142-2147.
7. Bohle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol. 2003;170:964-969.
8. Atkins H, Davies BR, Kirby JA, Kelly JD. Polarisation of a T-helper cell immune response by activation of dendritic cells with CpG-containing oligonucleotides: a potential therapeutic regime for bladder cancer immunotherapy. Br J Cancer. 2003;89:2312-2319.
9. Herr HW. Age and outcome of superficial bladder cancer treated with bacille Calmette-Guerin therapy. Urology. 2007;70:65-68.
10. Herr HW. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. J Urol. 2005;174:2134-2137.
11. Mintz PJ, Kim J, Do KA, et al. Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol. 2003;21:57-63.
12. Zlotta AR, Drowart A, Huygen K, et al. Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette-Guerin (BCG) in patients with superficial bladder cancer. Clin Exp Immunol. 1997;109:157-165.
13. Hansson Y, Paulie S, Larsson A, Lundblad ML, Perlmann P, Naslund I. Humoral and cellular immune reactions against tumor cells in patients with urinary bladder carcinoma. Correlation between direct and antibody-dependent cell-mediated cytotoxicity. Cancer Immunol Immunother. 1983;16:23-29.
14. Studer UE, deKernion JB, Lovrekovich H, Lovrekovich L. Quantitative measurements of humoral immune response in mice to a FANFT induced bladder tumor. Urol Res. 1985;13:123-130.
15. Pasqualini R, Arap W, Rajotte D, Ruoslahti E. In vivo selection of phage-display libraries. In: Barbas CF 3rd, Burton DR, Scott JK, Silverman GJ, eds. Phage Display: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2000:1-24.
16. Zlotta AR, Van Vooren JP, Denis O, et al. What are the immunologically active components of bacille Calmette-Guerin in therapy of superficial bladder cancer? Int J Cancer. 2000;87:844-852.
17. Troye M, Hansson Y, Paulie S, Perlmann P, Blomgren H, Johansson B. Lymphocyte-mediated lysis of tumor cells in vitro (ADCC), induced by serum antibodies from patients with urinary bladder carcinoma or from controls. Int J Cancer. 1980;25:45-51.
18. Fuller KJ, Issels RD, Slosman DO, Guillet JG, Soussi T, Polla BS. Cancer and the heat shock response. Eur J Cancer. 1994;30A:1884-1891.
19. Schett G, Metzler B, Kleindienst R, et al. Myocardial injury leads to a release of heat shock protein (hsp) 60 and a suppression of the anti-hsp65 immune response. Cardiovasc Res. 1999;42:685-695.
20. Charo J, Geluk A, Sundback M, et al. The identification of a common pathogen-specific HLA class I A*0201-restricted cytotoxic T cell epitope encoded within the heat shock protein 65. Eur J Immunol. 2001;31:3602-3611.
21. Bruno S, Machi AM, Semino C, et al. Phenotypic, functional and molecular analysis of lymphocytes associated with bladder cancer. Cancer Immunol Immunother. 1996; 42:47-54.
22. Lamm DL, Thor DE, Winters WD, Stogdill VD, Radwin HM. BCG immunotherapy of bladder cancer: inhibition of tumor recurrence and associated immune responses. Cancer. 1981;48:82-88.
23. van der Meijden AP, Steerenberg PA, van Hoogstraaten IM, et al. Immune reactions in patients with superficial bladder cancer after intradermal and intravesical treatment with bacillus Calmette-Guerin. Cancer Immunol Immunother. 1989;28:287-295.
24. van der Meijden AP, Sylvester R, Oosterlinck W, et al. EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ. Eur Urol. 2005;48:363-371.